A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant
Haematologica. 2024 Feb 8.
doi: 10.3324/haematol.2023.284544.
Online ahead of print.
1 Department of Hematology and Hematopoietic Cell Transplantation.
2 Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA.
3 Fred Hutchinson Cancer Center, Seattle, WA.
4 Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.
5 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
6 Department of Shared Resources-Clinical Trial Office.
7 Department of Clinical Research, City of Hope National Medical Center, Duarte, CA.
8 University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO.
9 Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.
10 Department of Hematology and Hematopoietic Cell Transplantation. ddiamond@coh.org.